NeuroFusion Labs
NeuroFusion Labs  |
|
|---|---|
 |
|
| Type | Private |
| Traded as | None |
| Industry | Neurotechnology, AI |
| Founded | 2016 |
| Founder | Dr. Alina Kapoor |
| Headquarters | London, United Kingdom |
| Area served | Global |
| Key people | Dr. Alina Kapoor (CEO), Marco Lin (CFO), Sarah Choi (Head of R&D) |
| Products | NeuroNet OS, Synapse Cloud |
| Services | Neuro-interface development, AI-enhanced therapy |
| Revenue | US$ 320 million (2024) |
| Operating income | US$ 65 million |
| Net income | US$ 48 million |
| Total assets | US$ 980 million |
| Total equity | US$ 700 million |
| Number of employees | 1,200+ |
| Parent | NeuroGroup Holdings |
| Subsidiaries | NeuroFusion Korea, NeuroFusion Canada |
| Website | https://neurofusionlabs.com |
NeuroFusion Labs is an advanced neurotechnology and artificial intelligence company founded in 2016 and based in London, United Kingdom. Founded by brain-machine interface pioneer Dr. Alina Kapoor, the company specializes in merging human neural activity with AI systems for therapeutic, cognitive, and industrial purposes.
Since its early days, NeuroFusion has been at the forefront of developing wearable neural processors and implantable devices to treat neurological disorders. Their flagship product, **NeuroNet OS**, is an FDA-approved system used in cognitive rehabilitation centers across North America and Europe.
In 2023, the company unveiled **Synapse Cloud**, a secure cloud ecosystem that allows seamless integration of neural data with enterprise AI platforms — significantly improving decision-making in healthcare, defense, and mental wellness.
With over 1,200 employees and neuroscience hubs in Singapore, Boston, and Zurich, NeuroFusion Labs is widely recognized for pushing the limits of what's possible in human-AI symbiosis. The company’s ethos is: *"Empowering Minds. Enhancing Futures."*